Despite treatment advances over the past decades, schizophrenia remains one of the most
severe psychiatric disorders that is associated with a chronic relapsing course and marked …

Context Weight gain, a common adverse effect of antipsychotic medications, is associated
with medical comorbidities in psychiatric patients. Objective To test the efficacy of lifestyle …

Background: An increasing body of evidence suggests that, in comparison to the general
population, patients with severe mental illnesses such as schizophrenia or bipolar disorder …

Excess deaths from cardiovascular disease are a major contributor to the significant
reduction in life expectancy experienced by people with schizophrenia. Important risk factors …

In recent years, we've developed a much better grasp of the biological and other factors
associated with the development of obesity. Reflecting our evolving understanding of …

Background: Numerous publications have provided evidence for clinically important
metabolic adverse effects of antipsychotics, but there is no systematic evaluation as to …

Compared with the general population, persons with schizophrenia have up to a 20%
shorter lifespan, with cardiovascular disease as the leading cause of death. In addition …

The presence of the metabolic syndrome is an important risk factor for cardiovascular
disease and diabetes. There are limited data on the prevalence of the metabolic syndrome …

Almost fifty years after its first introduction into clinical care, clozapine remains the only
evidence-based pharmacological option for treatment-resistant schizophrenia (TRS), which …

The present work focuses on the development of a new electrochemical platform based on
CoMn 2 O 4-rGO/1-ethyl-3-methylimidazolium chloride modified carbon paste electrode …